We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.

Publish with impact in OncoTargets and Therapy

Research impact is an important topic in the research world. Funders, institutions, and researchers themselves are all interested in assessing the quality and impact of research.

We’ve curated a collection of published articles from OncoTargets and Therapy based on their impact within the field—focusing on the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer and the evidence behind new and existing therapies that aid their informed acceptance by clinicians and treatment adherence by patients.

Explore the science behind these articles and increase your impact as a researcher by becoming our next published author.

Pexidartinib in the management of advanced tenosynovial giant cell tumor
Pexidartinib in the management of advanced tenosynovial giant cell tumor: focus on patient selection and special considerations
Anna Vaynrub, John H Healey, William Tap, Max Vaynrub
Columbia University Vagelos College of Physicians and Surgeons, New York, NY, USA; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Phase I trial of the MET/ALK/ROS1
A phase I trial of the MET/ALK/ROS1 inhibitor crizotinib combined with the VEGF inhibitor pazopanib in patients with advanced solid malignancies
Sarina A Piha-Paul, Ecaterina E Dumbrava, Binoj C Nair, Wendy Xiong, Li Xu, Rosa Mostorino, Vivek Subbiah, Nizar Tannir, Siqing Fu, Aung Naing, Filip Janku, Daniel D Karp, Shreyaskumar Patel, Najat C Daw, David Hong, Funda Meric-Bernstam, Ralph Zinner
Department of Investigational Cancer Therapeutics (A Phase I Clinical Trials Program), University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Breast Surgical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, USA; The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Medical Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA
PD-1 expression in pre-treatment follicular lymphoma
PD-1 expression in pre-treatment follicular lymphoma predicts the risk of subsequent high-grade transformation
Marie Beck Enemark, Ida Monrad, Charlotte Madsen, Kristina Lystlund Lauridsen, Bent Honoré, Trine Lindhardt Plesner, Stephen Jacques Hamilton-Dutoit, Francesco d’Amore, Maja Ludvigsen
Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark; Department of Biomedicine, Aarhus University, Aarhus, Denmark; Department of Pathology, Copenhagen University Hospital, Copenhagen, Denmark
Treatment of BRAF-mutated metastatic melanoma
Durable response to vemurafenib and cobimetinib for the treatment of BRAF-mutated metastatic melanoma in routine clinical practice
Mª del Carmen Álamo, Sebastian Ochenduszko, Guillermo Crespo, Mónica Corral, Juana Oramas, Pilar Sancho, Javier Medina, Fernando Garicano, Pedro López, Begoña Campos Balea, Analia Rodríguez Garzotto, Eva Muñoz-Couselo
Oncology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain; Oncology Department, Hospital Universitario Dr. Peset, Valencia, Spain; Oncology Department, Hospital Universitario de Burgos, Burgos, Spain; Oncology Department, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain; Oncology Department, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain; Oncology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain; Oncology Department, Hospital Universitario Virgen de la Salud, Toledo, Spain; Oncology Department, Hospital de Galdakao, Bizkaia, Spain; Oncology Department, Complejo Hospitalario General de Jaén, Jaén, Spain; Oncology Department, Hospital Lucus Augusti, Lugo, Spain; Medical Department and Strategy, Roche S.A, Madrid, Spain; Oncology Department, Hospital Universitario Vall d´Hebron, Barcelona, Spain; VHIO Vall d’Hebron Institute on Oncology, Barcelona, Spain
Metastatic esophagogastric carcinoma
Rapidly evolving treatment landscape for metastatic esophagogastric carcinoma: review of recent data
Lionel Aurelien Kankeu Fonkoua, Harry H Yoon
Department of Oncology, Mayo Clinic, Rochester, MN, USA; Department of Hematology, Mayo Clinic, Rochester, MN, USA
Treatment of metastatic castration-resistant prostate cancer
Clinical utility of olaparib in the treatment of metastatic castration-resistant prostate cancer: a review of current evidence and patient selection
Alexis LeVee, Ching Ying Lin, Edwin Posadas, Robert Figlin, Neil A Bhowmick, Dolores Di Vizio, Leigh Ellis, Charlos J Rosser, Michael R Freeman, Dan Theodorescu, Stephen J Freedland, Jun Gong
Department of Medicine, Division of Hematology and Oncology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Surgery, Division of Cancer Biology and Therapeutics, Biomedical Sciences, and Pathology and Laboratory Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Department of Surgery, Division of Urology, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Section of Urology, Durham VA Medical Center, Durham, NC, USA
Psychological resilience and health-related quality of life
Psychological resilience and health-related quality of life in Swedish women with newly diagnosed breast cancer
Åsa Mohlin, Ulrika Axelsson, Pär-Ola Bendahl, Carl Borrebaeck, Cecilia Hegardt, Per Johnsson, Ingalill Rahm Hallberg, Lisa Rydén
Department of Clinical Sciences Lund, Division of Medical History, Lund University, Lund, Sweden; Healthcare Center Laröd, Helsingborg, Sweden; Department of Immunotechnology and CREATE Health Translational Cancer Center, Lunds University, Lund, Sweden; Department of Clinical Sciences Lund, Division of Oncology and Pathology, Lund University, Lund, Sweden; Department of Psychology, Lund University, Lund, Sweden; Department of Health Sciences, Lund University, Lund, Sweden; Department of Clinical Sciences Lund, Division of Surgery, Lund University, Lund, Sweden; Department of Surgery, Skåne University Hospital, Malmö, Sweden
Other emergent treatment options for Myelofibrosis
Beyond Ruxolitinib: Fedratinib and other emergent treatment options for Myelofibrosis
Jan Philipp Bewersdorf, Sara Mohamed Jaszczur, Salma Afifi, Jennifer C Zhao, Amer M Zeidan
Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA; Department of Pharmacy, Yale, New Haven Hospital, New Haven, CT, USA; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA

Are you interested in publishing your next article with OncoTargets and Therapy?

Authors are encouraged to send an abstract to obtain a view from the Editor about the suitability of their paper. The Editor will perform a pre-submission check based on the subject matter vs the aims and scope of the journal and advise if it is suitable for submission.

Photo of OncoTargets and Therapy's Editor-in-Chief, Dr. Romano Editor-in-Chief: Dr. Gaetano Romano

Dr. Gaetano Romano is a Professor in the Department of Biology at Temple University in Philadelphia, Pennsylvania, U.S.A. In the course of his academic activities, Professor Romano has been conducting several research projects in the fields of tumor immunology, immunogenic cell death, cancer radiation therapy combined with immune checkpoint inhibitors, drug discovery and development in oncological programs, cancer stem cells, mechanisms leading to chemo- and/or radiation resistance in malignant cells, viral and non-viral vectors development for gene therapy, oncolytic viruses, viral oncology, detection of tumors markers in solid biopsies and in peripheral blood, isolation and enumeration of circulating tumor cells and/or circulating tumor DNA from the bloodstream and characterization of cell signaling systems in the context of cancer research, neurodegenerative disorders, and stem cell biology.

We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By closing this message, you are consenting to our use of cookies.